Imatinib regulatory update

The U.K.'s NICE issued a preliminary appraisal for Glivec imatinib from Novartis for the adjuvant treatment of gastrointestinal stromal tumors (GISTs) after

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE